Navigation Links
NanoBio Corporation Completes Interim Analysis of Phase 2 Clinical Trial in Onychomycosis
Date:3/20/2008

ANN ARBOR, Mich., March 20 /PRNewswire/ -- NanoBio Corporation announced today that it has seen promising results from an interim analysis of its phase 2 study of NB-002, a topical lotion for onychomycosis (nail fungus). Although the details remain confidential, the results clearly justify completing the study, according to NanoBio scientists.

"Allowing adequate time for subjects to grow out a clear nail after successfully treating the infection will enable us to generate data on complete cure, the primary endpoint required by the FDA for approval of drugs to treat onychomycosis," said James R Baker Jr., M.D., founder and chairman of NanoBio Corporation.

The ongoing randomized, double-blind, vehicle-controlled study involving 443 subjects is being conducted at 22 sites in the United States and Canada. The interim analysis was performed on the first 160 subjects from the trial to complete the 24 week assessment of clear nail growth. Final results will be available in the first quarter of 2009.

The analysis confirmed the outstanding safety profile of NB-002 seen in previous human and animal trials, Baker said. Results from a phase 1 study in onychomycosis, as well as preclinical data, indicated that the product can be safely applied to the skin at doses more than 1,000 times higher than the minimum concentration required to kill fungi. In total, over 900 subjects have been treated with the NB-002 formulation without significant skin irritation, systemic absorption, or other safety concerns.

"NB-002 exerts its effect locally by penetrating to reach the nail bed where dermatophytes responsible for onychomycosis reside. It then kills both active hyphae and spores, without irritating the epithelium or being systemically absorbed," Baker said.

"The absence of systemic absorption provides a significant advance for onychomycosis therapy in terms of safety. Current oral (systemic) drugs for onychomycosis pose risks of hepatic and cardiac toxicity, as well as the potential for drug interactions," Baker added.

NB-002 has documented fungicidal activity against numerous fungi involved in cutaneous infections, including Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, Microsporum canis and Candida albicans.

About Onychomycosis

Onychomycosis is a chronic, persistent fungal infection of the nail bed resulting in unsightly thickening and discoloration of the nail, which sometimes can be accompanied by pain and disability. According to Podiatry Today, more than 35 million people in the United States have onychomycosis. Estimates indicate that up to 50 percent of those affected by the disease do not receive treatment.

Systemic treatments represent well over 80 percent of the market today, but they have potential toxicity issues and have shown to have relapse rates of 40 percent or higher. The only approved topical treatment for onychomycosis has demonstrated an efficacy rate ranging from 5 percent to 12 percent.

About NanoBio

NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.


'/>"/>
SOURCE NanoBio Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. NanoBio Corporation Successfully Completes Phase 2b Study in Herpes Labialis
2. NanoBio(R) Corporation Completes $30 Million in Equity Funding by Meeting Key Development Milestones
3. NanoBio Corporation Presents Preclinical and Interim Clinical Data on Topical Treatments for Herpes Labialis and Onychomycosis at AAD 2008
4. Synbiotics Corporation Announces Human Submission for FluDetect(R)
5. Harris Corporation Teams with Cancer Treatment Services International to Advance Oncology Treatment
6. CEL-SCI Corporation Reports First Quarter Financial Results
7. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
8. Divine Corporations Personal Lubricants Shown to Block Cancer-causing Viruses in a Study by the National Cancer Institute
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Genzyme Corporation Selects Diplomat Specialty Pharmacy for 2008 Renagel Medicare Part D Assistance Program
11. CEL-SCI Corporation Announces 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... -- Mosaic Life Care, based in St. Joseph, Missouri , has ... of 58 clinics, located in 22 cities, and its flagship St. Joseph Medical Center. ... the delivery of health care to its patients, including the insurance, billing and collections ... ... Mosaic Life Care St. Joseph Medical Center ...
(Date:3/23/2017)... Executive Summary ... primary research (inputs from industry experts, companies, stakeholders) ... the analysis of global heart valve devices market ... Replacement Procedure By Technique (Mechanical, Bioprosthetic, Transcatheter Aortic ... Balloon Valvuloplasty, Transcatheter Mitral Valve Repair (TMVR)), By ...
(Date:3/23/2017)... March 23, 2017 ... Healthcare disease pipeline guide Primary Hyperoxaluria - Pipeline ... Primary Hyperoxaluria (Genito Urinary System And Sex Hormones) ... condition characterized by recurrent kidney and bladder stones. ... called oxalate. Symptoms include blood in the urine, ...
Breaking Medicine Technology:
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... two panels at the Advanced ERISA Benefit Claims Litigation seminar in Chicago, Illinois. ... the Administrative Record, The majority of cases litigated under ERISA involve claims for ...
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, ... their training and leads programs. , In February, 2017, Empower Brokerage introduced their ... Performance Partners is designed to teach how to maximize their sales efforts, as ...
(Date:3/24/2017)... , ... March 24, 2017 , ... “Vintage and Harvest ... retired minister and college Bible teacher residing in North Carolina with his wife, Anna ... have blessed them with six grandchildren. David is also the author of “Shadow and ...
(Date:3/23/2017)... , ... March 23, 2017 , ... A recent report ... entry into teacher preparation programs. The NCTQ report suggests, based on a review of ... would significantly improve teacher quality in the U.S. It argues that this higher bar ...
(Date:3/23/2017)... ... 23, 2017 , ... PAINWeekEnd (PWE) Oklahoma City, on April ... will be an educational and exciting program providing busy clinicians and allied healthcare ... pain. , Oklahoma is in a healthcare crisis. The state ranks 46th in ...
Breaking Medicine News(10 mins):